Reaction
Parvovirus B19 Infection reporting signals
As of the last recalculation, Parvovirus B19 Infection appears in 870 FAERS reports alongside 31 co-occurring drug terms. The strongest observed disproportionality signal is BASILIXIMAB (PRR 280.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Basiliximab | 119 | 280.3 | 283.2 |
| Tacrolimus Extended-Release Capsules | 519 | 245.0 | 246.0 |
| Tacrolimus Ointment 0.1% | 517 | 243.3 | 244.3 |
| Tacrolimus | 531 | 206.6 | 207.3 |
| Mycophenolate Mofetil Hydrochloride | 430 | 148.5 | 149.0 |
| Mycophenolate Mofetil | 429 | 148.1 | 148.6 |
| Anti-Thymocyte Globulin (Rabbit) | 47 | 147.3 | 148.2 |
| Valganciclovir Hydrochloride Powder, | 52 | 108.4 | 108.9 |
| Mycophenilic Acid | 80 | 101.6 | 102.0 |
| Ganciclovir | 40 | 98.0 | 98.3 |
| Ganciclovir Sodium | 40 | 94.7 | 95.1 |
| Thiotepa | 32 | 83.2 | 83.5 |
| Everolimus Tablets | 54 | 82.1 | 82.3 |
| Valganciclovir | 56 | 75.9 | 76.1 |
| Valganciclovir Hydrochloride | 56 | 75.9 | 76.1 |
| Mycophenolic Acid | 83 | 68.5 | 68.7 |
| Sirolimus | 34 | 62.8 | 62.9 |
| Prednisolone | 275 | 52.9 | 52.9 |
| Prednisolone Oral | 275 | 52.9 | 52.9 |
| Prednisolone Oral Solution | 275 | 52.8 | 52.9 |
| Fludarabine Phosphate | 49 | 31.5 | 31.6 |
| Cyclosporine | 123 | 30.6 | 30.7 |
| Methylprednisolone | 141 | 28.9 | 29.0 |
| Everolimus | 55 | 27.5 | 27.6 |
| Busulfan | 16 | 24.8 | 24.8 |
| Melphalan | 16 | 17.1 | 17.1 |
| Erythropoietin | 14 | 16.5 | 16.6 |
| Blinatumomab | 7 | 16.2 | 16.2 |
| Melphalan Hydrochloride | 16 | 15.5 | 15.5 |
| Darbepoetin Alfa | 30 | 13.8 | 13.8 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 3 | 6.5 | 6.5 |